Increasing the High Throughput of a Luminescence-Based Serum Bactericidal Assay (L-SBA).

functional assay high throughput luminescent SBA serum bactericidal assay vaccine

Journal

Biotech (Basel (Switzerland))
ISSN: 2673-6284
Titre abrégé: BioTech (Basel)
Pays: Switzerland
ID NLM: 9918383086206676

Informations de publication

Date de publication:
18 Sep 2021
Historique:
received: 06 08 2021
revised: 02 09 2021
accepted: 16 09 2021
entrez: 13 7 2022
pubmed: 14 7 2022
medline: 14 7 2022
Statut: epublish

Résumé

Serum bactericidal assay (SBA) is the method to investigate in vitro complement-mediated bactericidal activity of sera raised upon vaccination. The assay is based on incubating the target bacteria and exogenous complement with sera at different dilutions and the result of the assay is represented by the sera dilution being able to kill 50% of bacteria present in the inoculum. The traditional readout of the assay is based on measurement of colony-forming units (CFU) obtained after plating different reaction mixes on agar. This readout is at low throughput and time consuming, even when automated counting is used. We previously described a novel assay with a luminescence readout (L-SBA) based on measurement of ATP released by live bacteria, which allowed to substantially increase the throughput as well as to reduce the time necessary to perform the assay when compared to traditional methods. Here we present a further improvement of the assay by moving from a 96-well to a 384-well format, which allowed us to further increase the throughput and substantially reduce costs while maintaining the high performance of the previously described L-SBA method. The method has been successfully applied to a variety of different pathogens.

Identifiants

pubmed: 35822773
pii: biotech10030019
doi: 10.3390/biotech10030019
pmc: PMC9245470
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Front Immunol. 2018 Jan 17;8:1916
pubmed: 29387052
Genome Res. 2009 Dec;19(12):2279-87
pubmed: 19901036
Lancet Infect Dis. 2005 Oct;5(10):623-8
pubmed: 16183516
Clin Vaccine Immunol. 2014 May;21(5):712-21
pubmed: 24623629
PLoS One. 2015 Aug 06;10(8):e0134478
pubmed: 26248044
PLoS One. 2017 Dec 29;12(12):e0189100
pubmed: 29287062
Int J Mol Sci. 2021 Jan 28;22(3):
pubmed: 33525644
Clin Vaccine Immunol. 2011 Aug;18(8):1252-60
pubmed: 21715580
Lancet Infect Dis. 2018 Nov;18(11):1229-1240
pubmed: 30266330
PLoS Negl Trop Dis. 2015 Mar 04;9(3):e0003573
pubmed: 25739091
PLoS One. 2017 Feb 13;12(2):e0172163
pubmed: 28192483
Front Immunol. 2021 May 04;12:671325
pubmed: 34017343
Hum Vaccin Immunother. 2014;10(6):1478-93
pubmed: 24804797
Lancet. 2018 Nov 10;392(10159):1736-1788
pubmed: 30496103
mSphere. 2018 Jun 13;3(3):
pubmed: 29898979
J Clin Invest. 2008 Apr;118(4):1553-62
pubmed: 18357343
Hum Vaccin. 2010 Nov;6(11):881-7
pubmed: 21339701
Proc Natl Acad Sci U S A. 2020 Sep 29;117(39):24443-24449
pubmed: 32900928
Curr Protoc Microbiol. 2011 Nov;Chapter 6:Unit6A.3
pubmed: 22045586
J Infect Dev Ctries. 2012 Nov 26;6(11):763-73
pubmed: 23277501
Proc Natl Acad Sci U S A. 2018 Oct 9;115(41):10428-10433
pubmed: 30262653
Vaccine. 2017 Jan 11;35(3):419-426
pubmed: 27998639
Vaccine. 2006 Jun 12;24(24):5093-107
pubmed: 16838413
Nat Rev Microbiol. 2007 Jul;5(7):540-53
pubmed: 17558427
Lancet. 2012 Jun 30;379(9835):2489-2499
pubmed: 22587967
PLoS Med. 2006 Sep;3(9):e353
pubmed: 16968124
Sci Rep. 2021 Jan 13;11(1):906
pubmed: 33441861
J Immunol Methods. 2018 Oct;461:117-121
pubmed: 29969587
Vaccines (Basel). 2021 Apr 27;9(5):
pubmed: 33925465
Clin Infect Dis. 2017 Apr 15;64(8):1066-1073
pubmed: 28158395
Vaccine. 2009 Jun 24;27 Suppl 2:B20-9
pubmed: 19477053
BMC Infect Dis. 2016 Sep 05;16:473
pubmed: 27595992
PLoS One. 2012;7(11):e47039
pubmed: 23144798
Vaccines (Basel). 2021 Mar 06;9(3):
pubmed: 33800727
High Throughput. 2020 Jun 08;9(2):
pubmed: 32521658
Vaccine. 2019 Aug 7;37(34):4778-4783
pubmed: 31358238
PLoS Pathog. 2012;8(10):e1002933
pubmed: 23055923
Microb Pathog. 2016 Aug;97:19-26
pubmed: 27216239

Auteurs

Maria Grazia Aruta (MG)

GSK Vaccines Institute for Global Health (GVGH) S.r.l., 53100 Siena, Italy.

Martina Carducci (M)

GSK Vaccines Institute for Global Health (GVGH) S.r.l., 53100 Siena, Italy.

Francesca Micoli (F)

GSK Vaccines Institute for Global Health (GVGH) S.r.l., 53100 Siena, Italy.

Francesca Necchi (F)

GSK Vaccines Institute for Global Health (GVGH) S.r.l., 53100 Siena, Italy.

Omar Rossi (O)

GSK Vaccines Institute for Global Health (GVGH) S.r.l., 53100 Siena, Italy.

Classifications MeSH